Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid‐associated osteoporosis in patients with ulcerative colitis

Kitazaki, Shigehiko; Mitsuyama, Keiichi; Masuda, Junko; Yamasaki, Hiroshi; Kuwaki, Kotaro; Takedatsu, Hidetoshi; Sugiyama, Gen; Takahashi, Osamu; Sata, Michio

doi:10.1111/j.1365-2036.2008.03899.x

Cited by 23 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No benefit was seen in the bisphosphonate group compared with the calcium/vitamin D supplement-alone group; however, both groups demonstrated improvements in BMD. Kitazaki et al performed a small randomized trial of 39 patents with UC on glucocorticoids, comparing alendronate to alfacalcidol, demonstrating a significant improvement (4.1%) in BMD in the aldendronate group at 6 and 12 months [42]. The 2003 future science group Diet, nutrition & inflammatory bowel disease Review American Gastrointestinal Association (AGA) guidelines for osteoporosis in gastrointestinal disease recommend that IBD patients with any of the following should be screened for osteoporosis with a dual energy x-ray absorptiometry (DEXA) scan: more than 3 months of corticosteroid use, low trauma fracture, postmenopausal female, male over 50 or hypogonadism [31].…”

Section: Nutritional Deficienciesmentioning

confidence: 96%

Diet, nutrition and inflammatory bowel disease

Hou¹,

Sellin²

2010

Therapy

View full text Add to dashboard Cite

Section: Nutritional Deficienciesmentioning

confidence: 96%

Diet, nutrition and inflammatory bowel disease

Hou¹,

Sellin²

2010

Therapy

View full text Add to dashboard Cite

“…Additionally, it has been shown that other medications and drugs have the potential to pass from the mother's bloodstream into breast milk and reach the nursing infant . Although clinical case studies have reported the benefits of BPs for the treatment of pregnancy and lactation‐associated osteoporosis (PLO), glucocorticoid‐induced osteoporosis, hypercalcemia, and other complications during pregnancy and lactation, data on the effects of BP exposure of the mother and possibly the offspring during pregnancy or lactation remains limited.…”

Section: Introductionmentioning

confidence: 99%

Pamidronate Administration During Pregnancy and Lactation Induces Temporal Preservation of Maternal Bone Mass in a Mouse Model of Osteogenesis Imperfecta

Olvera

Stolzenfeld

Fisher

et al. 2019

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

During pregnancy and lactation, the maternal skeleton undergoes significant bone loss through increased resorption to provide the necessary calcium supply to the developing fetus and suckling neonate. This period of skeletal vulnerability has not been clearly associated with increased maternal fracture risk, but these physiological conditions can exacerbate an underlying metabolic bone condition like osteogenesis imperfecta. Although bisphosphonates (BPs) are commonly used in postmenopausal women, there are cases where premenopausal women taking BPs become pregnant. Given BPs’ long half‐life, there is a need to establish how BPs affect the maternal skeleton during periods of demanding metabolic bone changes that are critical for the skeletal development of their offspring. In the present study, pamidronate‐ (PAM‐) amplified pregnancy‐induced bone mass gains and lactation‐induced bone loss were prevented. This preservation of bone mass was less robust when PAM was administered at late stages of lactation compared with early pregnancy and first day of lactation. Pregnancy‐induced osteocyte osteolysis was also observed and was unaffected with PAM treatment. No negative skeletal effects were observed in offspring from PAM‐treated dams despite lactation‐induced bone loss prevention. These findings provide important insight into (1) a treatment window for when PAM is most effective in preserving maternal bone mass, and (2) the maternal changes in bone metabolism that maintain calcium homeostasis crucial for fetal and neonatal bone development. © 2019 American Society for Bone and Mineral Research

show abstract

“…ALN is regarded as a first-line drug for the treatment of postmenopausal osteoporosis in Japan, because RCTs in postmenopausal Japanese women with osteoporosis revealed that ALN treatment (1–3 years) suppressed bone turnover, increased the bone mineral density (BMD), and reduced the incidence of vertebral fractures 7–10. RCTs in Japanese patients treated with glucocorticoid showed that ALN treatment (1–2 years) sustained or increased the lumbar spine BMD 11–13. Furthermore, a RCT in Japanese men with osteoporosis or osteopenia and clinical risk factors of fractures confirmed that ALN treatment (1 year) increased the total hip BMD 14…”

Section: Introductionmentioning

confidence: 99%

Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture

Iwamoto¹,

Satō²,

Uzawa³

et al. 2011

TCRM

View full text Add to dashboard Cite

Purpose:Combined treatment with alendronate and alfacalcidol is more useful to increase bone mineral density (BMD) than alendronate or alfacalcidol alone. A retrospective study was conducted to investigate the 3-year outcome of combined treatment with alendronate and alfacalcidol in patients with severe bone loss (BMD ≤ 50% of the young adult mean) and osteoporotic fracture.Methods:Thirty-four patients (six men and 28 postmenopausal women) with primary or secondary osteoporosis who had been treated with alendronate and alfacalcidol for more than 3 years were analyzed. The lumbar spine or total hip BMD and bone turnover markers were monitored, and the incidence of osteoporotic fractures was assessed.Results:The urinary level of cross-linked N-terminal telopeptides of type I collagen and serum level of alkaline phosphatase significantly decreased (−42.5% at 3 months and −18.9% at 3 years), and the lumbar spine BMD, but not the total hip BMD, significantly increased (14.8% at 3 years), compared with the baseline values. However, the incidence of vertebral and nonvertebral fractures was 26.5% and 2.9%, respectively, suggesting a high incidence of vertebral fractures.Conclusion:The results of the present study suggest that combined treatment with alendronate and alfacalcidol may be useful to reduce bone turnover and increase the lumbar spine BMD in patients with severe bone loss and osteoporotic fracture. However, its efficacy against vertebral fractures appears not to be sufficient. Thus, anabolic agents such as teriparatide should be taken into consideration as first-line drugs in patients with severe osteoporosis.

show abstract

Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid‐associated osteoporosis in patients with ulcerative colitis

Abstract: SUMMARY BackgroundBone loss is often observed in patients with ulcerative colitis, particularly if they require glucocorticoids.

Cited by 23 publications

References 32 publications

Diet, nutrition and inflammatory bowel disease

Diet, nutrition and inflammatory bowel disease

Pamidronate Administration During Pregnancy and Lactation Induces Temporal Preservation of Maternal Bone Mass in a Mouse Model of Osteogenesis Imperfecta

Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture

Contact Info

Product

Resources

About